Baicalin mitigates polycystic ovary syndrome‑associated non‑alcoholic fatty liver disease by inhibiting the AR/SREBP1 axis

Jin,Bi-Hui; Xu,Han; Zhang,Zi-Yan; Fan,Yu-Hang; Jiang,Chun-Yan; Qi,Shao-Long; Xiao,Chen-Yu; Fu,Xiao-Hua; Qian,Ling-Bo

doi:10.3892/ijmm.2025.5630

Baicalin mitigates polycystic ovary syndrome‑associated non‑alcoholic fatty liver disease by inhibiting the AR/SREBP1 axis

Authors:
- Bi-Hui Jin
- Han Xu
- Zi-Yan Zhang
- Yu-Hang Fan
- Chun-Yan Jiang
- Shao-Long Qi
- Chen-Yu Xiao
- Xiao-Hua Fu
- Ling-Bo Qian
View Affiliations

Affiliations: Center for Reproductive Medicine, Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China, Department of Physiology, School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang 310053, P.R. China, Department of Reproductive Endocrinology, Center for Reproductive Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 315300, P.R. China, Department of Vascular Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130031, P.R. China, Center for Reproductive Medicine, Department of Gynecology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China
Published online on: September 8, 2025 https://doi.org/10.3892/ijmm.2025.5630
Article Number: 189
Copyright: © Jin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine disorder frequently associated with metabolic disturbances, such as non‑alcoholic fatty liver disease (NAFLD), driven by hyperandrogenism‑induced lipogenesis. Baicalin (BA), a flavonoid derived from Scutellaria baicalensis, exhibits therapeutic potential in the treatment of PCOS; however, the specific mechanisms against PCOS‑associated NAFLD remain unclear. In the present study, a PCOS mouse model was established via subcutaneous implantation of dihydrotestosterone. Model validation confirmed irregular estrous cycles, ovarian histopathological abnormalities and altered serum hormone levels. Treatment with BA markedly alleviated NAFLD‑associated metabolic abnormalities, including central obesity, dyslipidemia and hepatic steatosis. Moreover, liver transcriptomics indicated that BA modulated lipid metabolism primarily through sterol regulatory element‑binding protein 1 (SREBP1)‑mediated lipogenesis. Results of western blot analysis confirmed that BA suppressed hepatic protein expression of SREBP1 and its downstream lipogenic enzymes, fatty acid synthase and acetyl‑CoA carboxylase, indicating inhibition of hepatic lipogenesis. As androgen receptor (AR) functions as an upstream transcriptional regulator of SREBP1, network pharmacological analysis highlighted AR as a potential target of BA. Molecular docking predicted the BA‑AR binding site, guiding purification of truncated AR protein for isothermal titration calorimetry (ITC). Subsequently ITC was used to confirm the specific BA‑AR binding affinity. Luciferase reporter assays in MDA‑kb2 cells demonstrated that BA inhibited AR transcriptional activity. Collectively, the results of the present study indicated that BA ameliorates PCOS‑associated NAFLD through targeting the AR/SREBP1 axis, highlighting its potential as a therapeutic strategy for managing lipid metabolism disorders in PCOS.

View Figures

View References

1	Siddiqui S, Mateen S, Ahmad R and Moin S: A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS). J Assist Reprod Genet. 39:2439–2473. 2022. View Article : Google Scholar : PubMed/NCBI
2	Xu Q, Zhang J, Lu Y and Wu L: Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome. iScience. 27:1087832024. View Article : Google Scholar : PubMed/NCBI
3	Vidal-Cevallos P, Mijangos-Trejo A, Uribe M and Tapia NC: The interlink between metabolic-associated fatty liver disease and polycystic ovary syndrome. Endocrinol Metab Clin North Am. 52:533–545. 2023. View Article : Google Scholar : PubMed/NCBI
4	Paschou SA, Polyzos SA, Anagnostis P, Goulis DG, Kanaka-Gantenbein C, Lambrinoudaki I, Georgopoulos NA and Vryonidou A: Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine. 67:1–8. 2020. View Article : Google Scholar
5	Kumarendran B, O'Reilly MW, Manolopoulos KN, Toulis KA, Gokhale KM, Sitch AJ, Wijeyaratne CN, Coomarasamy A, Arlt W and Nirantharakumar K: Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. PLoS Med. 15:e10025422018. View Article : Google Scholar : PubMed/NCBI
6	Wu J, Yao XY, Shi RX, Liu SF and Wang XY: A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis. Reprod Health. 15:772018. View Article : Google Scholar : PubMed/NCBI
7	Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, Racila A, Hunt S and Beckerman R: The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 64:1577–1586. 2016. View Article : Google Scholar : PubMed/NCBI
8	Swinnen JV, Ulrix W, Heyns W and Verhoeven G: Coordinate regulation of lipogenic gene expression by androgens: Evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc Natl Acad Sci USA. 94:12975–12980. 1997. View Article : Google Scholar : PubMed/NCBI
9	Li N, Li X, Ding Y, Liu X, Diggle K, Kisseleva T and Brenner DA: SREBP regulation of lipid metabolism in liver disease, and therapeutic strategies. Biomedicines. 11:32802023. View Article : Google Scholar : PubMed/NCBI
10	Seidu T, McWhorter P, Myer J, Alamgir R, Eregha N, Bogle D, Lofton T, Ecelbarger C and Andrisse S: DHT causes liver steatosis via transcriptional regulation of SCAP in normal weight female mice. J Endocrinol. 250:49–65. 2021. View Article : Google Scholar : PubMed/NCBI
11	Matsumoto H, Yamamoto Y, Shiota M, Kuruma H, Beraldi E, Matsuyama H, Zoubeidi A and Gleave M: Cotargeting androgen receptor and clusterin delays castrate-resistant prostate cancer progression by inhibiting adaptive stress response and AR stability. Cancer Res. 73:5206–5217. 2013. View Article : Google Scholar : PubMed/NCBI
12	Saxena N, Beraldi E, Fazli L, Somasekharan SP, Adomat H, Zhang F, Molokwu C, Gleave A, Nappi L, Nguyen K, et al: Androgen receptor (AR) antagonism triggers acute succinate-mediated adaptive responses to reactivate AR signaling. EMBO Mol Med. 13:e134272021. View Article : Google Scholar : PubMed/NCBI
13	Magni P, Macchi C, Morlotti B, Sirtori CR and Ruscica M: Risk identification and possible countermeasures for muscle adverse effects during statin therapy. Eur J Intern Med. 26:82–88. 2015. View Article : Google Scholar : PubMed/NCBI
14	Yaribeygi H, Maleki M, Butler AE, Jamialahmadi T and Sahebkar A: New insights into cellular links between sodium-glucose cotransporter-2 inhibitors and ketogenesis. J Cell Biochem. 123:1879–1890. 2022. View Article : Google Scholar : PubMed/NCBI
15	Hu Q, Zhang W, Wu Z, Tian X, Xiang J, Li L, Li Z, Peng X, Wei S, Ma X, et al: Baicalin and the liver-gut system: Pharmacological bases explaining its therapeutic effects. Pharmacol Res. 165:1054442021. View Article : Google Scholar : PubMed/NCBI
16	Dai J, Liang K, Zhao S, Jia W, Liu Y, Wu H, Lv J, Cao C, Chen T, Zhuang S, et al: Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis. Proc Natl Acad Sci USA. 115:E5896–e5905. 2018. View Article : Google Scholar : PubMed/NCBI
17	Jin BR and An HJ: Baicalin alleviates benign prostate hyperplasia through androgen-dependent apoptosis. Aging (Albany NY). 12:2142–2155. 2020. View Article : Google Scholar : PubMed/NCBI
18	Chan FL, Choi HL, Chen ZY, Chan PS and Huang Y: Induction of apoptosis in prostate cancer cell lines by a flavonoid, baicalin. Cancer Lett. 160:219–228. 2000. View Article : Google Scholar : PubMed/NCBI
19	Kim AR, Kim SN, Jung IK, Kim HH, Park YH and Park WS: The inhibitory effect of Scutellaria baicalensis extract and its active compound, baicalin, on the translocation of the androgen receptor with implications for preventing androgenetic alopecia. Planta Med. 80:153–158. 2014. View Article : Google Scholar : PubMed/NCBI
20	Xu X, Xu X, Wang X and Shen L: Baicalin suppress the development of polycystic ovary syndrome via regulating the miR-874-3p/FOXO3 and miR-144/FOXO1 axis. Pharm Biol. 61:878–885. 2023. View Article : Google Scholar : PubMed/NCBI
21	Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, et al: The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Br J Pharmacol. 177:3617–3624. 2020. View Article : Google Scholar : PubMed/NCBI
22	Jin J, Ma Y, Tong X, Yang W, Dai Y, Pan Y, Ren P, Liu L, Fan HY, Zhang Y, et al: Metformin inhibits testosterone-induced endoplasmic reticulum stress in ovarian granulosa cells via inactivation of p38 MAPK. Hum Reprod. 35:1145–1158. 2020. View Article : Google Scholar : PubMed/NCBI
23	Aflatounian A, Paris VR, Richani D, Edwards MC, Cochran BJ, Ledger WL, Gilchrist RB, Bertoldo MJ, Wu LE and Walters KA: Declining muscle NAD(+) in a hyperandrogenism PCOS mouse model: Possible role in metabolic dysregulation. Mol Metab. 65:1015832022. View Article : Google Scholar : PubMed/NCBI
24	American Veterinary Medical Association: AVMA Guidelines for the Euthanasia of Animals: 2020 edition. American Veterinary Medical Association; Schaumburg, IL: 2020
25	McLean AC, Valenzuela N, Fai S and Bennett SA: Performing vaginal lavage, crystal violet staining, and vaginal cytological evaluation for mouse estrous cycle staging identification. J Vis Exp. 15:e43892012.
26	Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
27	Kanehisa M and Goto S: KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar
28	Yu G, Wang LG, Han Y and He QY: ClusterProfiler: An R package for comparing biological themes among gene clusters. Omics. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
30	McRae JM, Falconer RJ and Kennedy JA: Thermodynamics of grape and wine tannin interaction with polyproline: implications for red wine astringency. J Agric Food Chem. 58:12510–12518. 2010. View Article : Google Scholar : PubMed/NCBI
31	Sato R: Sterol metabolism and SREBP activation. Arch Biochem Biophys. 501:177–181. 2010. View Article : Google Scholar : PubMed/NCBI
32	Audet-Walsh É, Vernier M, Yee T, Laflamme C, Li S, Chen Y and Giguère V: SREBF1 activity is regulated by an AR/mTOR nuclear axis in prostate cancer. Mol Cancer Res. 16:1396–1405. 2018. View Article : Google Scholar : PubMed/NCBI
33	Singh RK, Kumar S, Tomar MS, Verma PK, Kumar A, Kumar S, Kumar N, Singh JP and Acharya A: Putative role of natural products as protein kinase C modulator in different disease conditions. Daru. 29:397–414. 2021. View Article : Google Scholar : PubMed/NCBI
34	Barber TM, Kabisch S, Randeva HS, Pfeiffer AFH and Weickert MO: Implications of resveratrol in obesity and insulin resistance: A state-of-the-art review. Nutrients. 14:28702022. View Article : Google Scholar : PubMed/NCBI
35	He S, He X, Pan S and Jiang W: Exploring the mechanism of chuanxiong rhizoma against thrombosis based on network pharmacology, molecular docking and experimental verification. Molecules. 28:67022023. View Article : Google Scholar : PubMed/NCBI
36	Hu X, Shi W, Wei S, Zhang X and Yu H: Identification of (anti-) androgenic activities and risks of sludges from industrial and domestic wastewater treatment plants. Environ Pollut. 268:1157162021. View Article : Google Scholar
37	Guo HX, Liu DH, Ma Y, Liu JF, Wang Y, Du ZY, Wang X, Shen JK and Peng HL: Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet. Acta Pharmacol Sin. 30:1505–1512. 2009. View Article : Google Scholar : PubMed/NCBI
38	Gao Y, Liu J, Hao Z, Sun N, Guo J, Zheng X, Sun P, Yin W, Fan K and Li H: Baicalin ameliorates high fat diet-induced nonalcoholic fatty liver disease in mice via adenosine monophosphate-activated protein kinase-mediated regulation of SREBP1/Nrf2/NF-κB signaling pathways. Phytother Res. 37:2405–2418. 2023. View Article : Google Scholar : PubMed/NCBI
39	Shi H, Qiao F, Lu W, Huang K, Wen Y, Ye L and Chen Y: Baicalin improved hepatic injury of NASH by regulating NRF2/HO-1/NRLP3 pathway. Eur J Pharmacol. 934:1752702022. View Article : Google Scholar : PubMed/NCBI
40	Zhang J, Zhang H, Deng X, Zhang N, Liu B, Xin S, Li G and Xu K: Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice. Life Sci. 192:46–54. 2018. View Article : Google Scholar
41	Armanini D, Boscaro M, Bordin L and Sabbadin C: Controversies in the pathogenesis, diagnosis and treatment of PCOS: Focus on insulin resistance, inflammation, and hyperandrogenism. Int J Mol Sci. 23:41102022. View Article : Google Scholar : PubMed/NCBI
42	Chen S, Ruan Q, Bedner E, Deptala A, Wang X, Hsieh TC, Traganos F and Darzynkiewicz Z: Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cell lines. Cell Prolif. 34:293–304. 2001. View Article : Google Scholar : PubMed/NCBI
43	Wang L, Feng T, Su Z, Pi C, Wei Y and Zhao L: Latest research progress on anticancer effect of baicalin and its aglycone baicalein. Arch Pharm Res. 45:535–557. 2022. View Article : Google Scholar : PubMed/NCBI
44	Zhou HC, Du R, Wang H, Zeng FL, Shi K, Li JM and Zong Y: Advance in studies on pharmacokinetics of baicalin. Zhongguo Zhong Yao Za Zhi. 43:684–688. 2018.In Chinese. PubMed/NCBI
45	Lu JQ, Luo ZY, Sun C, Wang SM, Sun D, Huang RJ, Yang X, Ding Y and Wang G: Baicalin administration could rescue high glucose-induced craniofacial skeleton malformation by regulating neural crest development. Front Pharmacol. 15:12953562024. View Article : Google Scholar : PubMed/NCBI
46	Deng L, Jin Y, Zheng X, Yang Y, Feng Y, Zhou H and Zeng Q: Pharmacological and toxicological characteristics of baicalin in preventing spontaneous abortion and recurrent pregnancy loss: A multi-level critical review. Heliyon. 10:e386332024. View Article : Google Scholar : PubMed/NCBI